Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)
Xiaotian Zhang, Yakun Wang, Muyan Cai, Fenghua Wang, Tong Xie, Jianming Ying, Weiqi Sheng, Xiangshan Fan, Xiujuan Qu, Chang Wang, Zhi Peng, Jie’er Ying, Miaozhen Qiu, Tianshu Liu, Yueping Liu, Dongmei Lin, Xiaohong Yao, Ziyu Li, Wenlong Guan, Ruihua Xu, Jin Li, Hong Bu, Lin Shen · 2026
Read Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition) by Xiaotian Zhang, Yakun Wang, Muyan Cai, Fenghua Wang, Tong Xie, Jianming Ying, Weiqi Sheng, Xiangshan Fan, Xiujuan Qu, Chang Wang, Zhi Peng, Jie’er Ying, Miaozhen Qiu, Tianshu Liu, Yueping Liu, Dongmei Lin, Xiaohong Yao, Ziyu Li, Wenlong Guan, Ruihua Xu, Jin Li, Hong Bu, Lin Shen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13308193.txt.
Description
Xiaotian Zhang and a large expert panel update China’s guidance on HER2-targeted treatment for stomach and junction cancers, in the 2025 edition released in 2026. These cancers carry a heavy burden in China. The HER2 protein, when abundant on tumor cells, opens the door to a family of targeted drugs, but judging who qualifies has been crude.
The guideline refines HER2 status into four levels, from high down to absent, to sort patients more finely. It folds in better detection, including tissue stains, gene probes, and blood-based biopsy, to cope with tumors that vary from spot to spot. Newer agents, from antibodies to drug-linked antibodies and dual-target drugs, are placed in sequence. Uniform rules should smooth care across China’s hospitals.
Catalog record
| CREATOR | Xiaotian Zhang, Yakun Wang, Muyan Cai, Fenghua Wang, Tong Xie, Jianming Ying, Weiqi Sheng, Xiangshan Fan, Xiujuan Qu, Chang Wang, Zhi Peng, Jie’er Ying, Miaozhen Qiu, Tianshu Liu, Yueping Liu, Dongmei Lin, Xiaohong Yao, Ziyu Li, Wenlong Guan, Ruihua Xu, Jin Li, Hong Bu, Lin Shen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 84 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |